Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00184562 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PF-00184562 | DRUG | - |
| Olanzapine | DRUG | - |
Inclusion Criteria: * Healthy male or female subjects of non-childbearing potential Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active ...
PF-00184562 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and tolerability in early-stage trials.
PF-00184562 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting early-stage clinical research on this investigational compound for schizophrenia.
PF-00184562 is in Phase 1 clinical development. It is an investigational drug, meaning it has not received regulatory approval and is not yet available for clinical use. The Phase 1 trial has been completed, and the drug remains in early-stage development.
PF-00184562 has one completed clinical trial registered under NCT00150215, titled "A First In Human Study Of PF-00184562 In Healthy Volunteers." This Phase 1 study enrolled 18 participants in the United States and was a randomized, double-blind, uncontrolled trial.
No alternative names for PF-00184562 have been identified. The compound is known only by its developmental code name PF-00184562, and no other brand names or aliases have been reported in the available clinical trial information.